Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
48.66
-1.09 (-2.19%)
At close: Jun 16, 2025, 4:00 PM
48.62
-0.04 (-0.08%)
After-hours: Jun 16, 2025, 7:59 PM EDT
BMY Revenue
Bristol-Myers Squibb Company had revenue of $11.20B in the quarter ending March 31, 2025, a decrease of -5.60%. This brings the company's revenue in the last twelve months to $47.64B, up 4.62% year-over-year. In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth.
Revenue (ttm)
$47.64B
Revenue Growth
+4.62%
P/S Ratio
2.07
Revenue / Employee
$1,396,950
Employees
34,100
Market Cap
99.03B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
BMY News
- 18 hours ago - Bristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel) - Business Wire
- 4 days ago - Dividend Harvesting Portfolio Week 223: $22,300 Allocated, $2,310.77 In Projected Dividends - Seeking Alpha
- 4 days ago - Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 - Business Wire
- 4 days ago - Bristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025 - Business Wire
- 5 days ago - Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 days ago - Bristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis - Business Wire
- 6 days ago - Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties - GlobeNewsWire
- 6 days ago - 5 Ideal 'Safe' Buys From June Fortune Return On Leadership Screen - Seeking Alpha